



PB 17 of 2025

National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (March Update) Instrument 2025

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the *National Health Act 1953*.

Dated 24 February 2025

REBECCA RICHARDSON

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division

Contents

1	Name.....	1
2	Commencement.....	1
3	Authority	1
4	Schedules.....	1
Schedule 1—Amendments		2
<i>National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021)</i>		<i>2</i>

1 Name

- (1) This instrument is the *National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (March Update) Instrument 2025*.
- (2) This instrument may also be cited as PB 17 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. <i>The whole of this instrument</i>	<i>1 March 2025</i>	<i>1 March 2025</i>

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 100(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021)

[1] Section 30A

repeal the section, substitute:

30A Paragraph 99AAAB(1)(b) of the Act does not apply to certain HSD pharmaceutical benefits

Paragraph 99AAAB(1)(b) of the Act does not apply to a special arrangement supply of an HSD pharmaceutical benefit if:

- (a) the manner of administration of the benefit is injection or extracorporeal circulation; and
- (b) the benefit is not a community access medication.

[2] Schedule 1, entry for Entecavir in the form Tablet 1 mg (as monohydrate)

omit:

Entecavir Mylan	C5037 C5044	60	5
-----------------	-------------	----	---

[3] Schedule 1, entry for Lenalidomide in the form Capsule 20 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

Lenalidomide Sandoz	C13782 C13786 C13787 C13803 C13805 C13812 C13813 C14362	See Schedule 2	See Schedule 2
---------------------	--	----------------	----------------